Top Menu

FDA Panel to Consider Approval of Drug for Smoking-Related Lung Damage


A panel of the Food and Drug Administration (FDA) this week will meet to decide whether to recommend approval of a new drug for smoking-related lung damage, Fox News reports. The drug, Breo, is an inhaled treatment for chronic obstructive pulmonary disease.

It received a better-than-expected initial review from the FDA, documents on the agency’s website suggest. The FDA reviewers said the drug’s overall safety was consistent with similar drugs.

Investors were concerned the FDA might focus on an increase in the number of pneumonia cases in patients treated with the drug, the article notes. The panel was not in agreement about the drug’s effectiveness. They are scheduled to meet Wednesday.
If approved, Breo would compete with the drugs Advair and Symbicort.

No responses yet.

Leave a Reply

Please read our comment policy and guidelines before you submit a comment. Your email address will not be published. Thank you for visiting

nine − = 1

Reproduction in whole or in part of this publication is strictly prohibited without prior consent. Photographic rights remain the property of Join Together and the Partnership for Drug-Free Kids. For reproduction inquiries, please e-mail